venBio Partners LLC — 13F Holdings & Portfolio

CIK 1776382 · latest 13F-HR filed 2026-08-14

venBio Partners LLC manages $519.4M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PHVS (30.92%), PBLS (27.75%), ALMS (24.53%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions and exited 1; 3 existing positions rose in reported value and 1 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$519.4M

Long-equity book

Holdings
7

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+2 / −1 / ↑3 / ↓1

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 100%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 12, 2026.

Address
1700 OWENS STREET
SUITE 595
SAN FRANCISCO, CA 94158-0008
Phone
(415) 800-0800
Name Title / Status Ownership Type
GOODMAN, COREY, S. ControlMANAGING DIRECTOR
since Jan 2018
Less than 5%Individual
Gaster, Richard, Samuel ControlMANAGING DIRECTOR
since Apr 2020
Less than 5%Individual
Pezeshki, David ControlCFO & COO
since Jun 2017
Less than 5%Individual
ROYSTON, AARON ControlMANAGING DIRECTOR
since Apr 2019
Less than 5%Individual
VENBIO PARTNERS, L.P. ControlOWNER
since Jan 2018
75% or moreDomestic Entity
ADELMAN, ROBERT Control
Indirect owner via VENBIO PARTNERS, L.P.
LIMITED PARTNER
since Jan 2018
25–50%Individual
GOODMAN, COREY, S. Control
Indirect owner via VENBIO PARTNERS, L.P.
LIMITED PARTNER
since Jan 2018
25–50%Individual
Gaster, Richard, Samuel Control
Indirect owner via VENBIO PARTNERS, L.P.
LIMITED PARTNER
since Jul 2021
25–50%Individual
ROYSTON, AARON Control
Indirect owner via VENBIO PARTNERS, L.P.
LIMITED PARTNER
since Apr 2019
25–50%Individual
VENBIO PARTNERS MANAGEMENT HOLDINGS GP, LLC Control
Indirect owner via VENBIO PARTNERS, L.P.
GENERAL PARTNER
since Jan 2018
General partner, trustee or managerDomestic Entity
Ownership & leadership changes · 6 filings with changes since Sep 28, 2017

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 12, 2026 filing
  • No longer listedADELMAN, ROBERT · MANAGING DIRECTOR · Less than 5% · control person · listed since Jan 2018
Mar 7, 2025 filing
  • No longer listedDelhonte, Antoinette · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Aug 2021
  • ChangedGaster, Richard, Samuel · title DIRECTOR → MANAGING DIRECTOR
  • ChangedPezeshki, David · title CHIEF OPERATING OFFICER → CFO & COO
  • ChangedROYSTON, AARON · title DIRECTOR → MANAGING DIRECTOR
Mar 24, 2022 filing
  • AddedDelhonte, Antoinette · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • AddedGaster, Richard, Samuel · LIMITED PARTNER · 25–50% · indirect via VENBIO PARTNERS, L.P. · control person
  • ChangedPezeshki, David · title CHIEF FINANCIAL OFFICER → CHIEF OPERATING OFFICER
Mar 19, 2021 filing
  • AddedGaster, Richard, Samuel · DIRECTOR · Less than 5% · control person
Mar 18, 2020 filing
  • AddedROYSTON, AARON · DIRECTOR · Less than 5% · control person
  • AddedROYSTON, AARON · LIMITED PARTNER · 25–50% · indirect via VENBIO PARTNERS, L.P. · control person
  • ChangedADELMAN, ROBERT · indirect via VENBIO PARTNERS, L.P.: ownership 50–75% → 25–50%
  • ChangedGOODMAN, COREY, S. · indirect via VENBIO PARTNERS, L.P.: ownership 50–75% → 25–50%
Mar 27, 2018 filing
  • AddedADELMAN, ROBERT · LIMITED PARTNER · 50–75% · indirect via VENBIO PARTNERS, L.P. · control person
  • AddedGOODMAN, COREY, S. · LIMITED PARTNER · 50–75% · indirect via VENBIO PARTNERS, L.P. · control person
  • AddedVENBIO PARTNERS MANAGEMENT HOLDINGS GP, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via VENBIO PARTNERS, L.P. · control person
  • AddedVENBIO PARTNERS, L.P. · OWNER · 75% or more · control person
  • ChangedADELMAN, ROBERT · ownership 25–50% → Less than 5%
  • ChangedGOODMAN, COREY, S. · ownership 25–50% → Less than 5%
Sep 28, 2017 filing (earliest on record)
  • ListedADELMAN, ROBERT · MANAGING DIRECTOR · 25–50% · control person
  • ListedGOODMAN, COREY, S. · MANAGING DIRECTOR · 25–50% · control person
  • ListedPezeshki, David · CHIEF FINANCIAL OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 3 →

Top Trims

Show all 1 →

venBio Partners LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PHARVARIS N V PHVS N69605108 $160.6M 30.92% 4,643,430 SH
2 PARABILIS MEDICINES INC PBLS 698955101 $144.1M 27.75% 5,266,697 SH
3 ALUMIS INC ALMS 022307102 $127.4M 24.53% 4,528,408 SH
4 ACHIEVE LIFE SCIENCE INC QUIT 004468500 $38.6M 7.44% 5,914,720 SH
5 ALX ONCOLOGY HLDGS INC ALXO 00166B105 $26.7M 5.14% 12,884,638 SH
6 HARMONY BIOSCIENCES HLDGS IN HRMY 413197104 $17.2M 3.31% 472,194 SH
7 LYELL IMMUNOPHARMA INC LYEL 55083R203 $4.7M 0.91% 337,697 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $519.4M 7 0000905148-26-003741
2026-03-31 2026-05-15 $280.6M 6 0000905148-26-002409
2025-12-31 2026-02-17 $216.3M 6 0000905148-26-000841
2025-09-30 2025-11-14 $176.4M 6 0000905148-25-004034
Filer Information
Address
1700 OWENS STREET, SUITE 595
SAN FRANCISCO, CA 94158
Phone
(415) 522-0100
Filing Manager
venBio Partners LLC
SAN FRANCISCO, CA
Signatory
David Pezeshki
Chief Financial Officer